Breaking News Instant updates and real-time market news.

DBVT

DBV Technologies

$7.35

-0.92 (-11.12%)

06:41
10/09/19
10/09
06:41
10/09/19
06:41

DBV Technologies 15.829M share Spot Secondary priced at $6.59

Goldman Sachs and Citi acted as joint book running managers for the offering.

  • 05

    Aug

  • 09

    Oct

DBVT DBV Technologies
$7.35

-0.92 (-11.12%)

09/16/19
MSCO
09/16/19
NO CHANGE
Target $11
MSCO
Equal Weight
Aimmune panel meeting holds 'three key positives' for DBV, says Morgan Stanley
Morgan Stanley analyst Vikram Purohit sees "three key positives" for the prospects for DBV Technologies' (DBVT) Viaskin Peanut from the FDA advisory committee meeting to discuss AR101, a competing peanut allergy immunotherapy being developed by Aimmune (AIMT). Namely, he thinks there was a clear consensus that peanut allergy presents a true unmet need; the panel maintained an intense focus on safety, where Viaskin Peanut has been differentiated; and the backing of AR101 increases the odds of that treatment being approved, which would help define a regulatory pathway for Viaskin Peanut. Purohit views the panel as a positive sentiment driver for DBV shares, but continues to believe that the key overhang on the stock is the FDA decision to accept or reject the Viaskin Peanut BLA resubmission. The analyst maintains an Equal Weight rating on DBV shares.
10/04/19
PIPR
10/04/19
NO CHANGE
Target $60
PIPR
Overweight
Piper stays positive on Aimmune after FDA accepts DBV application
Piper Jaffray analyst Christopher Raymond says the FDA's acceptance of competitor DBV Technologies' (DBVT) Biologics License Application submission for Viaskin Peanut does not change his positive outlook on Aimmune Therapeutics (AIMT). Today's decision means that DBV has addressed the FDA's manufacturing-related concerns that precipitated withdrawal of the original BLA submission late last year, Raymond tells investors in a research note. The analyst, however, still thinks Viaskin Peanut's approvability "remains open for debate given its relatively meager effect size" and failure of the Phase Pepites trial. Further, DBV still faces an FDA panel before an approval decision, and even if it ultimately wins FDA approval, Aimmune's Palforzia "retains the clear competitive edge," contends Raymond. The analyst keeps an Overweight rating on shares of Aimmune with a $60 price target. The stock in afternoon trading is down 4.5% to $22.46.
10/04/19
GSCO
10/04/19
NO CHANGE
Target $14
GSCO
Buy
BLA acceptance a de-risking event for DBV Technologies, says Goldman Sachs
Goldman Sachs analyst Graig Suvannavejh called the FDA's acceptance of DBV Technologies' (DBVT) Biologics License Application for Viaskin Peanut a "de-risking event," especially in light of the uncertainty caused by DBV having previously withdrawn its original BLA at the end of 2018. While investors debate the efficacy of Viaskin Peanut, Suvannavejh sees safety, tolerability and ease of use potentially driving better patient uptake when compared to Aimmune's (AIMT) competing Palforzia. He has a Buy rating on DBV with a $14 price target for the American Depositary Shares.
10/07/19
HCWC
10/07/19
NO CHANGE
Target $25
HCWC
Buy
DBV filing acceptance a 'constructive step forward,' says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein believes Friday's Biologics License Application acceptance as a "constructive step forward" for DBV Technologies (DBVT) in light of a potential perceived overhang for the program related to the Phase 3 Pepites trial. Despite Viaskin Peanut having displayed significant difference in responder rates compared to placebo in the Phase 3 Pepites trial, the question remains as to how the FDA ultimately perceives Viaskin Peanut not meeting its pre-determined 15% lower bound confidence interval between treatment groups, which was reported at 12.4%, Fein tells investors in a research note. The FDA being receptive to evaluate Viaskin Peanut's data package suggests that that Viaskin may not possibly need an 'efficacy homerun" for potential approval and that the company's approach to data analytics could be acceptable, adds the analyst. He reiterates a Buy rating on DBV shares with a $25 price target. Fein continues to believe the risk of anaphylaxis requiring epinephrine could ultimately help to give an edge to DBV's Viaskin Peanut patch over Aimmune's (AIMT) Palforzia.

TODAY'S FREE FLY STORIES

09:25
10/14/19
10/14
09:25
10/14/19
09:25
General news
Oil Action: Front-month WIT are down 2.3% »

Oil Action: Front-month…

ZLAB

Zai Lab

$32.38

0.01 (0.03%)

09:25
10/14/19
10/14
09:25
10/14/19
09:25
Conference/Events
Zai Lab participates in a conference call with JPMorgan »

SMid Biotechnology Equity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

AMZN

Amazon.com

$1,730.79

11.115 (0.65%)

09:24
10/14/19
10/14
09:24
10/14/19
09:24
Recommendations
Amazon.com analyst commentary  »

Loop Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 21

    Nov

F

Ford

$8.78

0.145 (1.68%)

09:22
10/14/19
10/14
09:22
10/14/19
09:22
Hot Stocks
Ford reports Q3 Europe sales up 3.1% to 313,400 vehicles »

Ford sales grew more than…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

ACM

Aecom

$37.14

0.35 (0.95%)

, LPG

Dorian LPG

$11.48

0.22 (1.95%)

09:21
10/14/19
10/14
09:21
10/14/19
09:21
Hot Stocks
Fly Intel: Pre-market Movers »

HIGHER: Aecom (ACM), up…

ACM

Aecom

$37.14

0.35 (0.95%)

LPG

Dorian LPG

$11.48

0.22 (1.95%)

LYFT

Lyft

$39.49

1.8 (4.78%)

WDC

Western Digital

$58.36

1.09 (1.90%)

FLXN

Flexion

$13.37

0.125 (0.94%)

AMTD

TD Ameritrade

$35.27

0.78 (2.26%)

IPGP

IPG Photonics

$136.12

6.24 (4.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

  • 07

    Nov

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

YNDX

Yandex

$29.95

-5.62 (-15.80%)

09:19
10/14/19
10/14
09:19
10/14/19
09:19
Recommendations
Yandex analyst commentary  »

Foreign ownership limit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

AMCX

AMC Networks

$48.42

0.89 (1.87%)

09:19
10/14/19
10/14
09:19
10/14/19
09:19
Downgrade
AMC Networks rating change  »

Evercore downgrades AMC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

SPX

S&P 500

$0.00

(0.00%)

, VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

09:18
10/14/19
10/14
09:18
10/14/19
09:18
Options
Overnight activity included 332 trades in SPX and 7 trades in VIX »

332 trades were executed…

SPX

S&P 500

$0.00

(0.00%)

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$169.06

1.255 (0.75%)

, ABBV

AbbVie

$73.66

1.39 (1.92%)

09:17
10/14/19
10/14
09:17
10/14/19
09:17
Hot Stocks
Allergan shareholders approve AbbVie acquisition proposal »

Allergan (AGN) announced…

AGN

Allergan

$169.06

1.255 (0.75%)

ABBV

AbbVie

$73.66

1.39 (1.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

TOL

Toll Brothers

$39.49

0.2 (0.51%)

09:16
10/14/19
10/14
09:16
10/14/19
09:16
Downgrade
Toll Brothers rating change  »

Toll Brothers downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBT

Global Blood Therapeutics

$46.49

0.61 (1.33%)

09:16
10/14/19
10/14
09:16
10/14/19
09:16
Recommendations
Global Blood Therapeutics analyst commentary  »

Global Blood Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

AMGN

Amgen

$200.76

2.05 (1.03%)

09:15
10/14/19
10/14
09:15
10/14/19
09:15
Initiation
Amgen initiated  »

Amgen resumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

JAZZ

Jazz Pharmaceuticals

$118.61

0.62 (0.53%)

09:13
10/14/19
10/14
09:13
10/14/19
09:13
Initiation
Jazz Pharmaceuticals initiated  »

Jazz Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBI

Pitney Bowes

$4.40

0.04 (0.92%)

09:13
10/14/19
10/14
09:13
10/14/19
09:13
Hot Stocks
Pitney Bowes issues statement on malware attack »

Pitney Bowes issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

INFY

Infosys

$10.97

-0.22 (-1.97%)

09:13
10/14/19
10/14
09:13
10/14/19
09:13
Downgrade
Infosys rating change  »

Infosys downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

ARGO

Argo Group

$67.34

1.4 (2.12%)

09:12
10/14/19
10/14
09:12
10/14/19
09:12
Hot Stocks
Argo Group holder Voce comments on SEC probe »

Voce Capital, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARW

Arrow Electronics

$74.22

1.095 (1.50%)

, TXN

Texas Instruments

$130.08

2.52 (1.98%)

09:11
10/14/19
10/14
09:11
10/14/19
09:11
Recommendations
Arrow Electronics, Texas Instruments analyst commentary  »

Longbow says Arrow…

ARW

Arrow Electronics

$74.22

1.095 (1.50%)

TXN

Texas Instruments

$130.08

2.52 (1.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

BKI

Black Knight

$61.68

0.39 (0.64%)

09:11
10/14/19
10/14
09:11
10/14/19
09:11
Hot Stocks
Black Knight receives to patents from USPTO »

Black Knight announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

UPS

UPS

$116.06

0.76 (0.66%)

09:10
10/14/19
10/14
09:10
10/14/19
09:10
Hot Stocks
UPS launches Storage on Demand service »

UPS announced the launch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

HON

Honeywell

$163.52

2.63 (1.63%)

09:09
10/14/19
10/14
09:09
10/14/19
09:09
Hot Stocks
Honeywell finalizing new T55 engine to power U.S. Army's Chinook helicopters »

Honeywell is finalizing a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

OKTA

Okta

$116.19

1.65 (1.44%)

, PING

Ping Identity

$16.47

0.45 (2.81%)

09:09
10/14/19
10/14
09:09
10/14/19
09:09
Initiation
Okta, Ping Identity, Zscaler, Crowdstrike initiated  »

Citi expands Software…

OKTA

Okta

$116.19

1.65 (1.44%)

PING

Ping Identity

$16.47

0.45 (2.81%)

ZS

Zscaler

$48.16

0.81 (1.71%)

CRWD

Crowdstrike

$60.24

-1.08 (-1.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 19

    Nov

  • 12

    Dec

  • 16

    Dec

ERIC

Ericsson

$8.44

0.2 (2.43%)

09:09
10/14/19
10/14
09:09
10/14/19
09:09
Hot Stocks
Ericsson and Watch Communications enter into partnership »

Watch Communications has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

OSTK

Overstock.com

$10.67

-0.18 (-1.66%)

09:08
10/14/19
10/14
09:08
10/14/19
09:08
Hot Stocks
Medici Land Governance signs MOU with St. Kitts and Nevis government »

Overstock.com announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMTL

Comtech

$31.24

0.51 (1.66%)

09:08
10/14/19
10/14
09:08
10/14/19
09:08
Hot Stocks
Comtech awarded $4.4M contract renewal »

Comtech announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RETA

Reata Pharmaceuticals

$95.80

9.86 (11.47%)

09:08
10/14/19
10/14
09:08
10/14/19
09:08
Recommendations
Reata Pharmaceuticals analyst commentary  »

Reata Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.